Details of Drug Interaction

Details of Drug-Drug Interaction

 Drug General Information (ID: DDI5ECU69Z)
  Drug Name Carteolol (ophthalmic) Drug Info Formoterol Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antihypertensive Agents Sympathomimetics
  Structure

 Mechanism of Carteolol (ophthalmic)-Formoterol Interaction (Severity Level: Major)
     Antagonize the effect of bronchodilators Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Carteolol (ophthalmic) Formoterol
      Mechanism Bronchospasm effects
Beta-2 adrenergic receptor  Antagonist 		Bronchodilator effects
Beta-2 adrenergic receptor  Agonist
      Key Mechanism Factor 1
Factor Name Adrenergic receptor beta-2
×
Structure Sequence
MGQPGNGSAFLLAPNGSHAPDHDVTQERDEVWVVGMGIVMSLIVLAIVFGNVLVITAIAKFERLQTVTNYFITSLACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSIDVLCVTASIETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQMHWYRATHQEAINCYANETCCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQLQKIDKSEGRFHVQNLSQVEQDGRTGHGLRRSSKFCLKEHKALKTLGIIMGTFTLCWLPFFIVNIVHVIQDNLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCLRRSSLKAYGNGYSSNGNTGEQSGYHVEQEKENKLLCEDLPGTEDFVGHQGTVPSDNIDSQGRNCSTNDSLL
Gene Name ADRB2
Uniprot ID ADRB2_HUMAN
KEGG Pathway hsa:154
Protein Family G-protein coupled receptor 1 family
Protein Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
    Click to Show/Hide
      Mechanism Description
  • Antagonize the effect of Formoterol when combined with Carteolol (ophthalmic) 

Recommended Action
      Management Concomitant use of beta-2 adrenergic bronchodilators with beta-blockers, including ophthalmic formulations, should generally be avoided. If coadministration is required, a cardioselective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol) is usually preferred. Nevertheless, caution is advised and respiratory status should be closely monitored, as cardioselectivity is not absolute and larger doses of beta-1 selective agents may pose some of the same risks as nonselective agents. In general, nonselective beta-blockers are considered contraindicated in patients with obstructive airways disease.

References
1 Craig TJ "Drugs to be used with caution in patients with asthma." Am Fam Physician 54 (1996): 947-53.[PMID: 8784166]
2 Chafin CC, Soberman JE, Demirkan K, Self T "Beta-blockers after myocardial infarction: Do benefits ever outweigh risks in asthma?." Cardiology 92 (1999): 99-105.[PMID: 10702651]
3 Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988): s18-24.[PMID: 2464094]